Barclays’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,500
| Closed | -$99.6K | – | 5146 |
|
|
2025
Q4 | $99.6K | Sell |
1,500
-34,900
| -96% | -$2.26M | ﹤0.01% | 4585 |
|
|
2025
Q3 | $2.45M | Sell |
36,400
-27,400
| -43% | -$2.17M | ﹤0.01% | 2736 |
|
|
2025
Q2 | $5.57M | Buy |
63,800
+28,800
| +82% | +$2.26M | ﹤0.01% | 2031 |
|
|
2025
Q1 | $2.39M | Hold |
35,000
| – | – | ﹤0.01% | 2494 |
|
|
2024
Q4 | $2.72M | Hold |
35,000
| – | – | ﹤0.01% | 2666 |
|
|
2024
Q3 | $2.35M | Buy |
+35,000
| New | +$2.87M | ﹤0.01% | 2725 |
|
|
2024
Q2 | – | Sell |
-35,500
| Closed | -$4.92M | – | 4983 |
|
|
2024
Q1 | $4.92M | Sell |
35,500
-213,200
| -86% | -$26.8M | ﹤0.01% | 1866 |
|
|
2023
Q4 | $30.9M | Buy |
+248,700
| New | +$25.4M | 0.01% | 880 |
|
|
2023
Q2 | – | Sell |
-175,500
| Closed | -$20.4M | – | 4672 |
|
|
2023
Q1 | $20.4M | Sell |
175,500
-3,700
| -2% | -$414K | 0.01% | 834 |
|
|
2022
Q4 | $20.3M | Buy |
+179,200
| New | +$19.7M | 0.01% | 884 |
|
|
2022
Q1 | – | Sell |
-20,400
| Closed | -$2.74M | – | 5108 |
|
|
2021
Q4 | $2.74M | Buy |
+20,400
| New | +$2.93M | ﹤0.01% | 2171 |
|
|
2020
Q2 | – | Sell |
-400
| Closed | -$27K | – | 5704 |
|
|
2020
Q1 | $27K | Buy |
+400
| New | +$24.9K | ﹤0.01% | 5534 |
|
|
2019
Q3 | – | Sell |
-160,000
| Closed | -$5.99M | – | 6792 |
|
|
2019
Q2 | $5.99M | Buy |
+160,000
| New | +$5.03M | ﹤0.01% | 1706 |
|
|
2018
Q4 | – | Sell |
-90,000
| Closed | -$3.22M | – | 7022 |
|
|
2018
Q3 | $3.22M | Sell |
90,000
-110,000
| -55% | -$3.41M | ﹤0.01% | 2317 |
|
|
2018
Q2 | $4.75M | Buy |
200,000
+196,000
| +4,900% | +$4.16M | ﹤0.01% | 1764 |
|
|
2018
Q1 | $74K | Sell |
4,000
-52,800
| -93% | -$781K | ﹤0.01% | 5601 |
|
|
2017
Q4 | $815K | Buy |
56,800
+54,800
| +2,740% | +$712K | ﹤0.01% | 3319 |
|
|
2017
Q3 | $24K | Sell |
2,000
-82,800
| -98% | -$1.46M | ﹤0.01% | 5713 |
|
|
2017
Q2 | $1.55M | Buy |
84,800
+83,600
| +6,967% | +$1.54M | ﹤0.01% | 2479 |
|
|
2017
Q1 | $25K | Buy |
+1,200
| New | +$23.4K | ﹤0.01% | 5702 |
|
|
2013
Q4 | – | Sell |
-45,600
| Closed | -$319K | – | 7565 |
|
|
2013
Q3 | $319K | Buy |
+45,600
| New | +$289K | ﹤0.01% | 4574 |
|
Other funds holding DXCM
VCM
VPM
Barclays's DXCM Position: Q1 2026 in Review
Barclays reduced its DexCom (DXCM) stake by 16% in Q1 2026, selling an estimated $15M and leaving 1,124,334 shares worth $70.6M. The position accounts for 0.02% of the portfolio, ranked #614.
Barclays first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $178M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Barclays held 1,124,334 shares of DexCom worth $70.6M as of Q1 2026.
- Barclays sold 215,122 DexCom shares in Q1 2026, an estimated $15M.
- DexCom made up 0.02% of Barclays's portfolio in Q1 2026, its #614 holding.
- Barclays first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
- Barclays's DexCom position peaked at $178M in Q1 2024.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.